课题基金 / 基金详情

Analysis of CYP2D6 gene haplotype in patients of juvenile onset Parkinson disease

Analysis of CYP2D6 gene haplotype in patients of juvenile onset Parkinson disease
青少年发病帕金森病患者CYP2D6基因单倍型分析
批准号:
06670658
负责人:
FURUYA Hirokazu
金额:
$1.41万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1994
资助国家:
日本
项目状态:
已结题
起止时间:
1994 至 1995

项目摘要

项目成果

FURUYA Hirokazu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Juvenile onset Parkinson disease (YOPD) is one of subtype of Parkinson disease (PD), but its onset age of symptom is below 40 and some cases have a genetic background. Since its symptoms are homogenous, it is considered to be suitable for analysis of genetic background. Cytochrome P450 debrisoquine hydroxylase (CYP2D6) has been regarded as one of the main genetic factor in PD.So, we analyze relationships between YOPD and CYP2D6 by determing haplotype of CYP2D6 gene polymorphisms.Genomic DNA samples are extracted from 8 YOPD, 18 PD and 55 age matched normal control. The B mutation in CYP2D6 are detected with the method by Smith et al and Hha I RFLP in exon 6 by Tuneoka et al. In Caucasian populatiopn, it is reported that the frequency of B mutation homozygous genotype (poor metabolizer of debrisoquine hydroxylase) is quite high in PD.But on the contrary, we found that its frequency is quite low in Japanese population and is not useful for genetic marker.Next, we use Hha I RFLP, which is rather high frequency in Japanese population. In conclusion, there is no mutation homozygous type, which is reported to be rather high frequency in Caucasian PD, is not found in Japanese YOPD and PD sample. Furthermore, there are no different allele frequency of Hha I RFLP between YOPD, PD and normal control. These results indicate that there is a possibility that CYP2D6 is not the risk factor of PD or YOPD.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
Yokota H: "cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria" J Biol Chem. 269. 23192-23196 (1994)
Yokota H:“人二氢嘧啶脱氢酶的 cDNA 克隆和染色体图谱,一种与 5-氟尿嘧啶毒性和先天性胸腺嘧啶尿嘧啶尿症相关的酶”J Biol Chem。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yasutake T: "Molecular analysis of X-linked adrenoleukodystrophy patients" J Neurol Sci. 131. 58-64 (1995)
Yasutake T:“X连锁肾上腺脑白质营养不良患者的分子分析”J Neurol Sci。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Furuya H: "Genetic polymorphism CYP2C9 and its effect on warfarin maintenance dose repuirement in patients undergoing anticoagulation therapy" Pharmacogenetics. (in press).
Furuya H:“CYP2C9 基因多态性及其对接受抗凝治疗的患者华法林维持剂量需求的影响”药物遗传学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yokota H, Fernandez-Salguero P, Furuya H, et al.: "cDNA cloning and chromosome mapping of human dihydropyrimidine dchydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria." J Biol Chem. 269. 23192-23196 (1994)
Yokota H、Fernandez-Salguero P、Furuya H 等人:“人二氢嘧啶脱氢酶的 cDNA 克隆和染色体图谱,这是一种与 5-氟尿嘧啶毒性和先天性胸腺嘧啶尿嘧啶尿症相关的酶。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
7
    Analysis of the effect with the, expanded CTG repeat for cell toxicity, especially tauopathy in the central nervous system in patietnt of myotonic dystrophy type 1 (DM 1)
    • 批准号:
      14570608
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.05万
    • 财政年份:
      2002
    • 负责人:
      FURUYA Hirokazu
    • 依托单位:
    Research for pathogenesis of adult onset Krabbe disease and basic approach for its gene therapy
    • 批准号:
      08670714
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.41万
    • 财政年份:
      1996
    • 负责人:
      FURUYA Hirokazu
    • 依托单位:
    海外基金